Key result
Pharmacological treatments for PAD lack large RCTs and rely on extrapolated CAD evidence.
Why the study?
Large well-designed RCTs and evidence-based guidelines for PAD management are lacking, with current practice standards often extrapolated from coronary artery disease.
This narrative review highlights the current pharmacological management strategies for peripheral arterial disease, emphasizing the need for more PAD-specific randomized controlled trials.
Background: Peripheral arterial disease (PAD) is a complex, heterogeneous condition that has become a leading health concern globally. Peripheral arterial disease often co-exists with other vascular disease states, including cerebrovascular and cardiovascular disease. Optimal therapy for managing symptoms and progression of disease employs non-pharmacological, pharmacological, and contemporary revascularisation techniques to improve clinical outcomes and quality of life. However, large well-designed randomised control trials (RCT) and corresponding evidence-based guidelines for management of PAD are lacking, with current practice standards often extrapolated from evidence in coronary artery disease. Purpose: This review article aims to discuss currently accepted best pharmacological practice for PAD. Method: Relevant articles were searched between May 2023 and January 2024 through PubMed, Cochrane Library, Google Scholar and international guidelines, focusing on pharmacological management for PAD. Results: This narrative review discusses holistic pharmacological treatments for PAD.
No takes yet. Share an insight, caveat, or question.
Leatham et al. (2024) conducted a review in Peripheral arterial disease. Pharmacological treatments was evaluated. Pharmacological treatments for peripheral arterial disease currently lack large randomized controlled trials, with practice standards often extrapolated from coronary artery disease evidence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: